With a little momentum at the end of 2018, Pfizer Inc. could be headed for its best year yet in the 21st century. The big pharma stock is absolutely crushing the performance of the overall market.
It's not that Pfizer's sales are soaring. The drugmaker missed analyst revenue estimates in the third quarter and probably will generate revenue in full-year 2018 only 2% higher than what it made in 2017. But Pfizer is a company in transition -- a positive one that Wall Street appears to now be recognizing.
It's not that Pfizer's sales are soaring. The drugmaker missed analyst revenue estimates in the third quarter and probably will generate revenue in full-year 2018 only 2% higher than what it made in 2017. But Pfizer is a company in transition -- a positive one that Wall Street appears to now be recognizing.